Comparison · NCT00004859-sae
Arm A (Paclitaxel + Carboplatin + Radiation ) vs Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Paclitaxel + Carboplatin + Radiation ) vs Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide): serious adverse events. Trial comparisons, record NCT00004859-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00004859-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.768 | 0.716 | 0.813 | wilson | |
| Risk in group 2 | 0.865 | 0.82 | 0.899 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0964 | -0.159 | -0.0333 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.888 | 0.822 | 0.961 | log | |
| Odds ratio, group 1 over group 2 | 0.519 | 0.336 | 0.801 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm A (Paclitaxel + Carboplatin + Radiation ) than on Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide) | 10.4 | 6.29 | 30.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Paclitaxel + Carboplatin + Radiation ) | Active comparator. Induction dosing: Paclitaxel, 225 mg/m²; Carboplatin, AUC=6.0. Concurrent dosing: Paclitaxel, 45 mg/m2; Carboplatin: AUC=2. | 222 | 289 | EG000 |
| Group 2 | Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide) | Experimental arm. Thalidomide: daily, patients begin with 200 mg thalidomide PO as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg; low dose aspirin: 81mg PO daily.~Paclitaxel, carboplatin and radiation same as active comparator. | 249 | 288 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Toxicity assessment was conducted weekly during chemotherapy,every other month for 24 months during follow up, every 6 months once >24 months from study entry to 5 years.
Source ClinicalTrials.gov
Trial
- Title
- Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
- NCT number
- NCT00004859
- Phases
- PHASE3
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, thalidomide, radiation therapy
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2012-03-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00004859?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00004859-sae